Skip to main content

testosterone cypionate

Generic: TESTOSTERONE CYPIONATE·Brand: AZMIRO, DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE

testosterone cypionate: 7 clinical trials tracked.

testosterone cypionate evidence translation

What we can confirm

7 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about testosterone cypionate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (7)

A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553Registry updated 2026-08-04·Phase 2/Phase 3
Not yet recruiting

Primary endpoint: Change in lower limb fat-free mass

InterventionalRandomizedquadruple300 targetStarted 2027-10Completion 2032-034 sites · United StatesVA Office of Research and Development

A Randomized Phase II/III Trial Evaluating Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07852195Registry updated 2026-10-01·Phase 2/Phase 3
Not yet recruiting

Primary endpoint: Second progression-free survival (PFS2) (Phase II)

InterventionalRandomizedopen432 targetStarted 2027-01Completion 2030-03ECOG-ACRIN Cancer Research Group

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318Registry updated 2025-09-17·Phase 2
Recruiting

Primary endpoint: Clinical/radiographic progression free survival (PFS) with BATZEN

Interventionalopen50 targetStarted 2025-08Completion 2031-081 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06305598Registry updated 2026-02-19·Phase 1
Recruiting

Primary endpoint: Androgen receptor (AR) activity

Interventionalopen14 targetStarted 2024-12Completion 2027-121 site · United StatesRoswell Park Cancer Institute

Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial

NCT06059118Registry updated 2026-01-14·Phase 2
Recruiting

Primary endpoint: PSA response rate at Cycle 1 Day 64

Interventionalopen50 targetStarted 2023-10Completion 2029-111 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

NCT04558866Registry updated 2026-02-12·Phase 2
Active, not recruiting

Primary endpoint: Rate of Radiographic Progression-Free Survival (rPFS)

Interventionalopen51 targetStarted 2021-06Completion 2026-066 sites · BrazilLatin American Cooperative Oncology Group

A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

NCT04363164Registry updated 2026-07-17·Phase 2
Recruiting

Primary endpoint: Clinical or Radiographic Progression free survival

InterventionalRandomizedopen150 targetStarted 2020-08Completion 2028-076 sites · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins